Our Services
Medical Information
Helpful Resources
Published on: 4/29/2026
Platelet-rich plasma therapy uses your own blood’s concentrated platelets to deliver growth factors that can stimulate retinal cell repair, protect photoreceptors and reduce inflammation in both dry and wet age-related macular degeneration. This minimally invasive treatment may slow vision loss, improve visual acuity and contrast sensitivity, and even delay the need for other interventions.
There are several important factors to consider, from risks such as transient pressure increases or inflammation to lifestyle changes, monitoring and combined therapies; see below for complete details on benefits, risks and next steps.
Age-related macular degeneration (AMD) affects millions worldwide, gradually stealing central vision used for reading, driving and recognizing faces. Platelet-rich plasma (PRP) therapy is emerging as a promising approach to slow or even partially reverse retinal damage. Below is a clear, step-by-step look at how PRP for macular degeneration works, why your vision may be fading, and what you can do next.
The macula sits at the center of your retina and is responsible for sharp, detailed vision. When it deteriorates, you may notice:
There are two main types:
Early detection is vital. If you're experiencing any of these warning signs, you can quickly assess your symptoms with a free Age-Related Macular Degeneration symptom checker to help determine your next steps.
Platelet-rich plasma (PRP) is a concentrate of platelets derived from your own blood. Platelets contain growth factors and proteins that support tissue repair and reduce inflammation. In ophthalmology, PRP can be repurposed to:
Because PRP is autologous (from your own body), it carries minimal risk of allergic reaction.
Macular degeneration progresses because of:
PRP aims to counteract these processes by supplying concentrated growth factors and anti-inflammatory proteins right where they're needed.
Early clinical studies and case reports suggest that PRP for macular degeneration may:
While generally well-tolerated, PRP injections carry some risks:
Your eye surgeon will discuss these risks and monitor you closely after treatment.
If you're noticing changes in your vision but aren't sure whether they warrant medical attention, take a few minutes to complete a confidential Age-Related Macular Degeneration symptom assessment powered by AI technology.
PRP for macular degeneration is an exciting frontier that leverages your body's own healing mechanisms. While not a cure, it may slow vision loss and, in some cases, improve sight. Talk openly with your eye doctor about benefits, risks and other available therapies. Early intervention is your best defense against central vision decline.
Disclaimer: This information is for educational purposes and does not replace professional medical advice. Always speak to a qualified healthcare provider about any vision changes or serious health concerns. If you experience sudden vision loss, severe eye pain or other alarming symptoms, seek immediate medical attention.
(References)
* Bakir B, Ozkagnici A, Gundogdu A. Platelet-Rich Plasma for Retinal and Optic Nerve Diseases: A Review of Clinical Efficacy and Basic Science. J Ocul Pharmacol Ther. 2022 Sep;38(7):437-446. doi: 10.1089/jop.2021.0125. Epub 2022 Aug 23. PMID: 36014443.
* Wang Y, Zhang X, Zhou H. Molecular mechanisms of platelet-rich plasma in ocular diseases: a systematic review. Regen Med. 2022 Aug;17(8):613-625. doi: 10.2217/rme-2021-0205. Epub 2022 May 25. PMID: 35624796.
* Cokkinos DD, Tsilimbaris MK, Kontadakis GA, Glynos AI, Charakidou A, Cokkinos DG. Platelet-Rich Plasma in the Treatment of Age-Related Macular Degeneration: A Systematic Review. Adv Ophthalmol. 2020 Feb 24;2020:6458514. doi: 10.1155/2020/6458514. PMID: 32095315; PMCID: PMC7058864.
* Pappa C, Kapetanios AD, Panagiotakopoulos KP, Zouridaki G, Tsakalakis V, Vlachos DE. Mechanisms of action of platelet-rich plasma in the treatment of age-related macular degeneration. Ther Adv Ophthalmol. 2020 Oct 19;12:2515841420967398. doi: 10.1177/2515841420967398. PMID: 33100224; PMCID: PMC7576922.
* Bakri SJ, Singh R, Han DP, Sheth BP, Sharma A, Kim JE, Iezzi R, Mittra R. Autologous Platelet-Rich Plasma as an Adjunctive Treatment in Neovascular Age-Related Macular Degeneration. Ophthalmic Surg Lasers Imaging Retina. 2016 Aug 1;47(8):724-31. doi: 10.3928/23258160-20160802-05. PMID: 27529681.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.